• RedHill Biopharma outlined its U.S. specialty pharma strategy focused on gastrointestinal disease, infectious disease, and oncology, centered on Talicia for Helicobacter pylori infection in adults.
• FY 2025 net revenues of USD 7.8 million, cash balance of USD 4.1 million, gross margin of 74.6%.
• Approximate market cap of USD 5.2 million, with about 5,200,000 American Depositary Shares outstanding.
• Equity financing capacity of USD 31.7 million, citing an at-the-market purchase agreement and a standby equity purchase agreement.
• Late-stage pipeline positioned around opaganib and RHB-102, with Talicia supported by U.S. patent protection to 2042 and QIDP market exclusivity through 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief on May 17, 2026, and is solely responsible for the information contained therein.